MAPT and early-onset autosomal dominant Alzheimer disease: TRx0237 is a derivative of MB in a stabilized and reduced form47 and failed to show clinical efficacy in Phase III clinical trials in Alzheimer’s disease patients (NCT01689246 and NCT01689233).49 Here, we found that MB, TRx0237, and raloxifene significantly inhibited dexamethasone-dependent activation of Tau phosphorylation at Ser422 (Supplementary information, Fig. S5d, e).